搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
6 小时
on MSN
Novartis to Buy Anthos Therapeutics From Blackstone for Up to $3.1 Billion
The pharma giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to boost its ...
MM&M
15 小时
Novartis buys back Anthos Therapeutics for up to $3.1B
Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...
BioSpace
19 小时
Novartis Bets Up to $3.1B to Buy Back Blood Thinner in Anthos Acquisition
Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.
The Pharma Letter
19 小时
Novartis to boost cardio pipeline with Anthos Therapeutics buy
Novartis today announced that it has entered into an agreement to acquire privately-held Anthos Therapeutics, which the Swiss ...
Contract Pharma
18 小时
Novartis to Acquire Anthos Therapeutics
Novartis has agreed to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical ...
22 小时
on MSN
Novartis buys Blackstone's Anthos for up to $3.1 billion
By Ludwig Burger and Ariane Luthi (Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a ...
BioPharma Dive
18 小时
Novartis pays $925M to reel in a startup it helped launch
The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...
11 天
on MSN
Novartis has cash for a big pharma deal—but here’s why it’s not buying
Novartis chief executive says large pharma deals usually don't pay off. But the company remains interested in bolt-on ...
FiercePharma
1 天
Novartis debuts €40M viral vector plant in Slovenia, part of €3.5B investment push in ...
Amid a broader push to beef up cell and gene therapy manufacturing capacity in Europe, Novartis has opened the doors to a €40 ...
1 天
Novartis Pharma AG: Novartis bolsters late-stage cardiovascular pipeline with agreement to ...
Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathwayAbelacimab is currently in P ...
MM&M
4 天
Novartis’ chief marketing officer on the drugmaker’s Super Bowl ad debut
Unlike other brands that release their ads days or weeks ahead of the Big Game, Novartis is waiting to unveil its commercial ...
1 天
M&A News: Novartis Seals $3.1B Deal to Acquire Anthos
Novartis (NVS) has sealed a $3.1 billion deal to acquire clinical-stage biopharmaceutical company Anthos Therapeutics. The ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈